【佳學(xué)基因靶向藥物基因檢測(cè)】p53 的高表達(dá)可預(yù)測(cè)食管鱗狀細(xì)胞癌中的生存不良而不是 TP53 突變

基因檢測(cè)機(jī)構(gòu)未來(lái)

挖掘基因檢測(cè)人員學(xué)習(xí)手冊(cè)聽到《J Oncol》在?2023 Jan 10;2023:3801526.發(fā)表了一篇題目為《》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Yan Jin,?Xueke Zhao,?Xin Song,?Ran Wang,?Zongmin Fan,?Panpan Wang,?Miaomiao Yang,?Fuyou Zhou,?Qide Bao,?Lidong Wang等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤基因檢測(cè)及靶向藥物治療研究關(guān)鍵詞：

TP53,腫瘤,抑癌基因,食管,鱗狀細(xì)胞癌

腫瘤治療檢測(cè)基因臨床應(yīng)用結(jié)果

TP53 是一種眾所周知的腫瘤抑制基因，也是人類癌癥中賊常見的遺傳改變之一。然而，p53 作為食管鱗狀細(xì)胞癌 (ESCC) 預(yù)后標(biāo)志物的作用在 TP53 改變與臨床結(jié)果之間的關(guān)聯(lián)中存在爭(zhēng)議。為了解決這個(gè)問(wèn)題，我們?cè)u(píng)估了大規(guī)模 ESCC 患者的 TP53 突變、p53 蛋白表達(dá)、臨床病理學(xué)參數(shù)和存活率。本研究包括兩個(gè)隊(duì)列：在 316 名 ESCC 患者中通過(guò)下一代測(cè)序檢測(cè)到 TP53 突變，在 6,028 名 ESCC 患者中通過(guò)免疫組織化學(xué)檢測(cè) p53 蛋白表達(dá)。使用 Kaplan-Meier 曲線和 Cox 比例風(fēng)險(xiǎn)模型進(jìn)行生存分析。 316例食管鱗癌患者中有241例（76.3%）存在TP53突變，6028例食管鱗癌患者（其中p53蛋白高表達(dá)1819例）p53蛋白陽(yáng)性表達(dá)率為59.1%。大多數(shù)突變是錯(cuò)義的，其中p53蛋白高表達(dá)。與野生型TP53相比，TP53基因突變與生存時(shí)間無(wú)顯著相關(guān)性(p=0.083)。在多變量分析中，p53 蛋白表達(dá)是 ESCC 的獨(dú)立預(yù)后因素。 p53 蛋白高表達(dá)組與低表達(dá)組相比，ESCC 患者的生存率較差（p < 0.001）。 p53 蛋白的高表達(dá)，而不是 TP53 突變，預(yù)示著 ESCC 患者的生存不佳，并且 p53 蛋白表達(dá)可能有可能成為 ESCC 的預(yù)后生物標(biāo)志物和治療靶點(diǎn)。

腫瘤發(fā)生與革命國(guó)際數(shù)據(jù)庫(kù)描述：

TP53?is a well-known tumor suppressor gene and one of the most common genetic alterations in human cancers. However, the role of p53 as a prognostic marker of esophageal squamous cell carcinoma (ESCC) is controversial in the association between?TP53?alterations and clinical outcomes. To address this issue, we evaluated?TP53?mutations, p53 protein expression, clinicopathological parameters, and survivals rates in a large scale of patients with ESCC. Two cohorts were included in this study:?TP53?mutations were detected by next-generation sequencing in 316 ESCC patients, and p53 protein expression was tested by immunohistochemistry in 6,028 ESCC patients. Survival analysis was performed using the Kaplan-Meier curve and the Cox proportional hazards model.?TP53?mutations were found in ESCC patients from 241 of 316 (76.3%), and the rate of positive expression of p53 protein was 59.1% in 6,028 ESCC patients (including 1819 with high expression of p53 protein), respectively. Most mutations were missense, which has a high expression of p53 protein. Compared with wild-typeTP53,?TP53?gene mutations were not significantly associated with survival time (p=0.083). In multivariate analysis, the p53 protein expression was an independent prognostic factor for ESCC. The high-expression group of p53 protein has poor survival (p?< 0.001) compared to low-expression group in patients with ESCC. The high expression of the p53 protein, not the?TP53?mutation, is predictive of poor survival in patients with ESCC, and p53 protein expression might have the potential to be a prognosis biomarker and therapy target in ESCC.